SereNeuro Closes Oversubscribed Pre-Seed to Move SN101 Toward IND

SereNeuro Therapeutics, a preclinical-stage biotechnology company based in Baltimore, announced the close of an oversubscribed pre-seed financing on October 5, 2026.

The company is developing non-opioid therapies for pain, placing it in the segment of drug development aimed at treating pain without relying on opioid mechanisms. SereNeuro did not disclose the size of the round, and the announcement named no lead investor or participating firms.

According to the announcement, the financing will advance the company's lead program, SN101, toward Investigational New Drug (IND)-enabling activities. Those activities represent the stage of preclinical work that precedes a company's application to begin testing a candidate in humans. The announcement did not specify which studies SN101 will undergo or a timeline for reaching that milestone.

The round also supports a second program, SN102, the company said. No additional detail on SN102 — its target, stage or indication — was provided.

The company described the financing as oversubscribed, indicating investor demand exceeded the amount SereNeuro had set out to raise. Even so, the absence of a stated figure, a named lead backer and a valuation leaves the round's scale and syndicate unknown from the announcement alone.

SereNeuro's SEC-filing history, prior capital raises and burn rate were not addressed in the announcement. The company's preclinical status means neither program has entered clinical testing, and any path to human trials for SN101 remains subject to the IND-enabling work the new capital is intended to fund.

For a preclinical biotech, the pre-seed stage typically precedes formal institutional rounds, but the announcement did not indicate whether SereNeuro plans a larger raise, when it expects to file an IND, or how long the current financing is expected to last.